High-risk HPV testing in women 30 years or older with negative papanicolaou tests: Initial clinical experience with 18-month follow-up

American Journal of Clinical Pathology

Volumn 133, Issue 6, 2010, Pages 894-898

  Thrall, Michael J ^a   Russell, Donna K ^b   Facik, Michael S ^b   Yao, Jorge L ^b   Warner, JulieAnn N ^c   Bonfiglio, Thomas A ^b   Giampoli, Ellen J ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

HPV; Human papillomavirus; Negative for intraepithelial lesion or malignancy; NILM; Papanicolaou test

Indexed keywords

ADULT; ARTICLE; CYTOLOGY; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; VERRUCA VULGARIS; WART VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PRACTICE GUIDELINE; RISK; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; PAPILLOMAVIRUS INFECTIONS; RISK; VAGINAL SMEARS;

EID: 77953013051     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPAZV88VIFZSFD     Document Type: Article

References (13)

1. Cuzick J, Clavel C, Petry K-U, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101. (Pubitemid 44116919)
2. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
3. Wright TC, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
4. Wright TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355.
5. VassarStats. http://faculty.vassar.edu/lowry/VassarStats.html. Accessed June 3, 2009.
6. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600.
7. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500.
8. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
9. Petry K-U, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003;88:1570-1577.
10. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765-774. (Pubitemid 43983300)
11. Bulkmans NWJ, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-1772.
12. Sargent A, Bailey A, Almonte M, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98:1704-1709. (Pubitemid 351684674)
13. Thrall MJ, Russell DK, Bonfiglio TA, et al. Use of the ThinPrep(R) Imaging System does not alter the frequency of interpreting Papanicolaou tests as atypical squamous cells of undetermined significance. Cytojournal. 2008;5:10. doi:10.1186/1742-6413-5-10.